greater sensitivity to CO2 leading to a larger ventilatory response for a given rise in the partial pressure of arterial CO2 (PaCO2) and resultant CSA with falls of PaCO2 driven by the consequent hyperventilation. 15 A number of factors predispose heart failure patients to develop nocturnal hypoxemia, which may play an important role in the further deterioration of heart failure and sleep structure and respiration. 16 A potential role of oxygen (O2) in correcting hypoxemia and reducing CSR, thereby improving CHF, has been suggested by previous studies. [16] [17] [18] [19] [20] [21] However, in these studies, the sampling size has been small, follow-up period short and the results inconclusive. In the present study, the efficacy of nasal O2 therapy at night using a conventional O2 concentrator on ventricular function, severity of heart failure, and quality of life (QOL), together with an improvement in sleep-disordered breathing (SDB) was assessed in ambulatory patients with stable CHF and CSR. In particular, because mortality of patients with heart failure is relatively low in Japan compared with Western populations, 22, 23 emphasis was placed on an improvement in QOL as an outcome measure.
Methods

Study Population
Ambulatory patients aged over 20 years with clinical evidence of CHF were enrolled from 20 centers if they met the following criteria: (1) symptomatic and New York Heart Association (NYHA) class II or III despite optimal medication for at least 2 weeks prior to entry, (2) LV ejection fraction (LVEF) determined by radionuclide angiography or left ventriculography within 6 months of the diagnostic sleep study ≤45%, (3) 4% oxygen desaturation index (ODI) of ≥5 dips/h on pulse oximetry, (4) at least 5 episodes of apnea and hypopnea per hour of sleep, of which more than 50% were central at screening test. 24 Exclusion criteria were: predominant obstructive sleep apnea (OSA), pregnancy, unstable angina, myocardial infarction within the previous 3 months, and significant renal, neurological, or respiratory disease.
The study protocol was approved by the Institutional Ethics Review Board and written informed consent was given by all patients prior to entry.
Study Design, Intervention and Procedures
Each patient was assessed by one of the investigators listed in the Appendix. At baseline before randomization and commencement of treatment, a comprehensive history was taken and a physical examination was performed. Each patient underwent routine clinical assessment including radiologic, electrocardiographic and echocardiographic studies and radionuclide or echocardiographic LVEF was determined.
In the preliminary study, the amount of O2 delivered was determined by pulse oximetry recordings in another group of 11 patients hospitalized with LV dysfunction and periodic oxygen desaturation (LVEF 40.8±17.0, ODI ≥5 dips/h). Patients received an incremental level of overnight nasal O2 for 3 nights (1, 2 and 3 L/min). Oxygen desaturation frequency was markedly reduced by 3 L/min of O2, ODI being less than 5 dips/h in all patients. On the basis of these findings, the O2 dosage was determined to be 3 L/min in this CHF-home oxygen therapy (HOT) study.
The investigators sent a fax to the coordinating center when they enrolled a new patient. Randomization was then performed according to the method of minimization by 5 factors (laboratory, age, sex, Specific Activity Scale score and ODI) and each patient was assigned to receive O2 at a rate of 3 L/min through nasal cannulae (HOT group) or to allow usual breathing for 12 weeks (control group).
O2 was delivered via 92% oxygen concentrator (TO-90-3N, Teijin Pharma Ltd, Japan). The patients assigned to the HOT were instructed to use nasal O2 for at least 6 h per night. Compliance was monitored by patients' reports and the inbuilt concentrator tachometer (TOMS ® , Teijin Pharma Ltd, Japan). Physical examination, assessment of the severity of heart failure (NYHA functional class) and the Specific Activity Scale 25 were repeated every 4 weeks. Polysomnography (PSG) or polygraphic recordings of cardiorespiratory parameters, assessment of LVEF and measurement of plasma norepinephine (NE) levels were performed at baseline and at the conclusion of the study at 12 weeks.
Outcome Variables SDB Indicators
The patients who met the inclusion criteria were monitored by PSG and if that was not available a cardiorespiratory monitoring device (Somté, Compumedics, Australia) was used. Oronasal signals detected by thermister were used as the respiratory sensors, thoracic and abdominal effort was measured by 2 belt sensors. Arterial O2 saturation (SpO2) was recorded by digital pulse oximetry (sampling frequency of 1 s). Surface lead electrocardiogram was also monitored throughout the night. The respiratory event detection and oximetry analysis were performed manually. The oximeter signal quality of the cardiorespiratory monitoring device was proved to be valid in comparison with PSG. 26 Home respiratory polygraphy has also been confirmed as a useful alternative to overnight PSG for diagnosis of SDB in heart failure. 27 Standard definitions were used for OSA and CSA on the basis of the presence or absence of rib cage and abdominal excursions with an absence of airflow. 24 OSA and CSA may coexist in the same individual and patients with OSA may have a waxing and waning pattern of breathing. These patients could be identified because they had a constant or increasing respiratory effort during the event. 24 Patients with purely or predominantly OSA were not included in this study. The ODI was the number of times per hour that the oxyhemoglobin saturation fell by 4% and the apneahypopnea index (AHI) was defined as the number of apneas and hypopneas per hour during the time in bed. CSR-CSA was defined as at least 3 cycles of a crescendo and decrescendo change in breathing amplitude. 24 Assessment of QOL We used the Specific Activity Scale as a measure of QOL in which self-perceived exercise tolerance is expressed by an energy cost spent with the maximal physical activities that the patient can perform. 25 Most of the exercise tests are designed to evaluate exercise performance at maximal workloads, but daily activities do not require an energy expenditure in the maximal range. In this regard, the Specific Activity Scale allows expression of the extent of submaximal physical activities.
We actually measured the metabolic costs of various types of physical activity by hooking subjects up to a mask to measure oxygen consumption and the volume of CO2 exhaled. Oxygen consumption can be estimated by the equa-
, where V • E is ventilation equivalent and [O2] is oxygen concentration units (ml/L). By definition, 1 Met is equivalent to a metabolic rate consuming 3.5 ml of oxygen per kilogram of body weight per minute. Next we prepared questionnaires about specific physical activities that a patient would perform either customarily or sporadically in daily life and each patient was asked to specify whether he/she could perform each type of activity without symptomatic limitation. Summarizing the questionnaire data, a given number of metabolic costs (Specific Activity Scale) were derived for each patient regarding the self-perceived exercise tolerance. As a clear linear correlation was observed between Specific Activity Scale and peak O2 consumption, 25 the Specific Activity Scale was considered to reliably predict exercise capacity.
Ventricular Function LVEF was followed up using either 99m Tc equilibrium radionuclide angiography or 2-dimensional (D) echocardiography at rest during the daytime while patients were awake. In each institution that participated in this study, all the measurements were performed by technicians in the individual laboratories, so they were unaware of the treatment allocation. Gated equilibrium radionuclide angiography was performed using the in vivo red blood cell labeling technique with initial intravenous stannous pyrophosphate followed by 99m Tc pertechnetate. LV time -activity curves were generated by the multiple gated acquisition program and the end-diastolic and endsystolic frames were determined from these 2-D echocardiographic images were acquired from the parasternal long and short axes, apical longitudinal axis, apical 4-chamber, and subcostal views. The LV end-diastolic and end-systolic dimensions were determined according to a modification of Simpson's method. LVEF was calculated as end-diastolic minus end-systolic volume divided by end-diastolic volume.
Plasma Concentration of NE Venous blood samples were drawn through an indwelling catheter in the forearm of each patient after they had lain quietly and undisturbed for at least 30 min. Plasma was immediately separated and stored at -70°C before the NE concentrations were determined by high performance liquid chromatography electrochemical detection.
Statistical Analysis
All statistical analyses were performed with StatView ® version 5.0 (Abacus Concepts, Calabasus, CA, USA) or SAS ® version 8.2 (Cary, NC, USA). Results are expressed as mean ± standard deviation (SD). The target number of patients was calculated to be 20 in each group, based on a 5% type I error, a 2-sided test, and an 80% power, using a t-test.
For the Specific Activity Scale, 2-way repeated measures analysis of variance (ANOVA) with 2 factors (group and time) was applied. When statistical significance was found in group × time interaction, post hoc analyses were performed.
For ODI, AHI, heart rate during sleep, LVEF, blood pressure and plasma NE levels, unpaired t-tests were used to compare data at each point between the control and HOT groups, as well as to compare changes in variables from baseline to the end of study between the 2 groups. Paired t-tests were used to compare within-group data at baseline and the end of the study. Changes in NYHA functional class were summed in each group and the differences in response were tested by Mann-Whitney U test. Missing values were imputed using the Last-Observation-CarriedForward approach. A value of p<0.05 was considered statistically significant.
Results
Patient Characteristics
Total of 68 patients were enrolled from 20 centers: 34 were randomly assigned to treatment with HOT and the remaining 34 maintained normal breathing with conventional therapy. Five patients (4 in the HOT group, and 1 in the control group) dropped out before the start of the trial because of withdrawal of consent or hospitalization because of worsening heart failure. There were 7 dropout cases (5 in HOT and 2 in the control group) during the 12-week study period because of violation of the protocol (changes in the underlying medication, discontinuation by patient request). Accordingly, 25 patients in the HOT group and 31 patients in the control group were assessed finally at 12 weeks. The characteristics of the patients are shown in Table 1 . There were no significant differences between the groups with respect to age, sex distribution, underlying heart disease, NYHA class, Specific Activity Scale values, LVEF or medications. ODI and AHI were also similar in both groups. The mean treatment hours per night with O2 were 8.50±0.90 h (range: 6.75-10.00 h), and the time in bed with normal breathing in the control group was 8.08±1.40 h (range: 6.25-11.00 h). Thus, compliance with HOT did not appear to be disturbed by the procedure. 
Effects of Supplemental O2 at Night on SDB
In the HOT group, supplemental O2 for 12 weeks significantly improved SDB, AHI being reduced from 21.0±10.8 to 10.0±11.6 events/h (p<0.001), and CSR being stabilized (Fig 2) . Although suppression of OSA was not observed, CSA and hypopnea indexes were significantly decreased (p=0.008 and <0.001, respectively) by HOT ( Table 2 ). The ODI was significantly reduced from 19.5±9.8 to 5.9± 8.7 dips/h (p<0.001) (Fig 2) . These values remained unchanged in the control group. There were no changes in Fig 2. Effects of home oxygen therapy (HOT) on the oxygen desaturation index (ODI) (A) and apnea/hypopnea index (AHI) (B). In the control group, ODI and AHI remained unchanged over the 12 weeks, but in the HOT, significant improvements in both parameters were observed. P values as compared with the control group at each time point were calculated by unpaired t-test. Mean ± SD. --, HOT; --, Control. heart rate or blood pressure in either group (Table 2) .
QOL According to Exercise Tolerance/Capacity
Physiology NYHA functional class improved in 28.0% of patients in the HOT group but in none of the control group (Table 3) .
In the HOT group, the Specific Activity Scale disclosed a significant improvement over time (p<0.001 by repeated measures ANOVA); initial values of Specific Activity Scale were almost the same in the 2 groups. Though these values remained unchanged in the control group (4.1±1.1 to 4.0±1.3 Mets), there was a progressive rise over the 12 weeks in the HOT group (4.0±1.2 to 5.0±1.5 Mets, p< 0.001), the difference between the groups being significant at 12 weeks (p=0.012) (Fig 3) .
LV Function
LVEF increased significantly from baseline to the end of the study (from 34.7±10.4 to 38.2±13.6%, p=0.022) in the HOT group but no change was seen in the control group (from 32.8±8.8 to 34.4±10.9%). The changes in LVEF from baseline to 12 weeks were 2.2±8.5 and 3.9±7.7% for the control and HOT groups respectively, but this difference did no reach statistical significance (Table 2) .
Plasma NE Concentration
The 12-week O2 therapy had no effect on plasma NE concentration in the blood samples obtained every 4 weeks in the early morning after quiet rest ( Table 2) .
Discussion
In previous studies done in selected patients with impaired LV systolic function, there has been a higher proportion of males and the relative occurrence of SDB is significantly greater in men than in women. 9, 28 However, a recent study of unselected patients admitted to hospital with decompensated chonic heart failure demonstrated no gender effect on SDB, 29 and the patients enrolled in the present study were similarly a random sample of heart failure patients with CSA. Therefore, the gender-dependent difference was not taken into account for the present analysis.
The nasal O2 therapy at night virtually eliminated arterial oxyhemoglobin desaturation and decreased the AHI to below 15. Nocturnal supplemental O2 has been shown to increase total sleep time, improve sleep quality, abolish CSR, [16] [17] [18] [19] [20] reduce sympathetic activity 19 and improve exercise capacity. 20 However, 4-week administration of O2 did not produce an improvement in cardiac function or QOL. 19 The results of the present study demonstrate that 12-week treatment with nocturnal O2 significantly improved NYHA functional class, Specific Activity Scale scores as a measure of QOL, along with an improvement of SDB in CHF patients with CSR-CSA. LVEF also increased from baseline to the end of the study.
Although there are many factors involved in the development of CSA, the decreased level of PaCO2 plays a major role and small changes in the PaCO2 by O2 administration can be associated with considerable improvement in CSA. 30, 31 Javaheri et al demonstrated that in the presence of low baseline PaCO2, sleep apnea and hypopnea continued even if desaturation was corrected by administration of O2. 18 Therefore, the overall therapeutic effect of oxygen relates to a widening of the difference between the prevailing PaCO2 and that of the apneic theshold. 18, 21 Andreas et al assumed that the addition of CO2 to O2 might achieve more effective suppression of CSR by increasing PaCO2 above the apneic threshold and performed a study to evaluate the effects of nocturnal CO2 + O2 on CSR, sleep and sympathetic activation, which revealed that the combination reduced the duration of CSR, increased arterial O2 saturation, as well as mean transcutaneous CO2 tension, but did not improve quality of sleep and increased sympathetic activation. Therefore, those authors concluded that the simple reduction of nocturnal CSR can not be the only objective in the management of patients with heart failure. 32 The therapeutic effects of O2 relate to an increase in O2 stores in the body and SpO2, thereby improving circulation time between the carotid body and the lung, dampening the respiratory control system and making it more stable. O2 also reduces the sensitivity of the respiratory control system with suppression of the hypercapnic ventilatory drive and the hypoxic ventilatory drive and increases the arterial partial pressure of O2 (PaO2) above the apneic theshold. 16, 33 The importance of an increase in PaO2 as well as in PaCO2 for eliminating apnea has been emphasized by Franklin et al that a large increase in PaO2 and only a small increase in PaCO2 were noted during oxygen therapy. 17 The results of the present study imply that the potential of nocturnal O2 to improve QOL by reducing CSR-CSA in patients with CHF. In Japanese trials of heart failure, the Specific Activity Scale is often used as a measure of QOL because it has been shown to reliably predict exercise capacity and physical activity in daily life. 26 The therapeu- Effect of oxygen on Specific Activity Scale. In the control group, the Specific Activity Scale remained unchanged throughout the study period, but increased gradually by 1.0±1.1 Mets in the HOT group, indicating a significant treatment effect in favor of oxygen therapy. Mean ± SD. P values as compared with the control group at each time point were calculated by unpaired t-test following 2-way repeated measures ANOVA. --, HOT; --, Control.
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tic goal of heart failure has recently been aimed at improving mortality in Western societies, but as mortality from heart disease is substantially lower in Japan than in all other Western countries, QOL is considered the primary goal of heart failure treatment in Japan. 22, 23 We observed that a 12-week trial of HOT resulted in a statistically significant increase in LVEF from baseline to the end of the study but no change was seen in the control group. Application of continuous positive airway pressure in patients with CHF and CSA-CSR has resulted in a significant improvement in LVEF over a 3-month period, 4, 34 attributed to a reduction of cardiac filling pressures, diastolic volumes and afterload in association with the decreased LV transmural pressure gradient. 35 It has been shown that CSR increases muscle sympathetic nerve activity (MSNA) in patients with CHF and induces transient elevations in blood pressure. 36 Therefore, an improvement in the daytime LVEF observed in the present study with nocturnal O2 may also be achieved in part by sustained reduction in afterload. It is clear that the mean LVEF is significantly lower in patients with sleep apnea than in those without, and there is a strong positive correlation between the AHI and an impairment of LVEF. 37 Thus, nocturnal O2 produces substantial decrease in AHI and this improvement may logically improve hypoxia-related LV dysfunction.
Andreas et al reported an increase in peak O2 consumption during bicycle exercise following 1 week of O2 therapy associated with an improvement in CSR, arousals, and nocturnal O2 saturation. 20 Subsequently, they demonstrated that O2 desaturation and CO2 retention increases MSNA, evaluated by microneurography of the peroneal nerve, during apnea and that O2 reduces this increase in MSNA. 38 Thus, those authors suggested that increased exercise tolerance with nocturnal O2 is mediated by a reduction in sympathetic nerve activity, which is increased by hypoxia and hypercapnea as well as arousals.
Apnea exerts a sympathoexcitatory effect by O2 desaturation and CO2 retention together with disappearance of sympathoinhibitory input from the intrathoracic receptors. 39 We observed no effect of O2 therapy on plasma NE levels. Staniforth et al also reported that overnight O2 therapy had no effect on early morning serum NE, which they attributed to the short half-life of serum NE and assumed that it would not be expected to remain elevated once SDB had ceased. They also measured urinary NE excretion as an integrated measurement of overnight serum NE concentration and actually confirmed an increased activation of sympathetic nervous activity in CSR, which could be reduced effectively by oxygen therapy. 19 Less severe disease states in terms of AHI (18.0 and 21 events/h) and LVEF (32.8 and 34.7%) in the present study could have rendered the change in NE in the daytime less prominent.
Despite recent evidence that SDB has adverse effects on patients with CHF, only limited attention has been paid to it as a potential therapeutic target. The O2 delivery system we used is likely to apply to many CHF patients and has great potential as a non-pharmacological treatment of CHF. However, the effects of supplemental O2 on morbidity and mortality over more prolonged periods have not been clarified 21 and further studies are warranted to elucidate the long-term benefits of nocturnal O2 in CHF patients.
